Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dimethyl sulfoxide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Dimethyl sulfoxide. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-002794-35 Sponsor Protocol Number: CPDR001F2301 Start Date*: 2017-02-20
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated pati...
    Medical condition: Unresectable or metastatic BRAF V600 mutant melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) AT (Completed) CZ (Completed) PL (Completed) BG (Completed) GR (Completed) BE (Completed) PT (Completed) NL (Completed) DK (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004459-19 Sponsor Protocol Number: CDRB436G2401 Start Date*: 2019-07-31
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)
    Medical condition: Children and Adolescents with Cancers Harboring V600 mutations
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021556-25 Sponsor Protocol Number: IBSA 01-2010 Start Date*: 2011-02-24
    Sponsor Name:IBSA
    Full Title: Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial ...
    Medical condition: Interstitial Cystitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018188 HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000168-27 Sponsor Protocol Number: CDRB436F2410 Start Date*: 2018-09-19
    Sponsor Name:Novartis Pharma AG
    Full Title: COMBI-APlus: Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evalua...
    Medical condition: Stage III BRAF V600 mutation-positive melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) FI (Completed) GB (GB - no longer in EU/EEA) LT (Completed) GR (Completed) SI (Completed) SK (Completed) BE (Completed) LV (Completed) HU (Completed) PT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004015-20 Sponsor Protocol Number: CDRB436G2201 Start Date*: 2018-01-09
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or...
    Medical condition: Paediatric patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) CZ (Completed) DE (Completed) ES (Ongoing) IT (Completed) FI (Completed) DK (Completed) FR (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005019-34 Sponsor Protocol Number: CTMT212X2106 Start Date*: 2016-05-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors
    Medical condition: Solid tumors, Pancreatic Cancer, Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003398-79 Sponsor Protocol Number: MH21HEM Start Date*: 2023-05-11
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C...
    Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001266-15 Sponsor Protocol Number: BRF115532 Start Date*: 2013-02-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 muta...
    Medical condition: High-risk BRAF V600 mutation-positive melanoma after surgical resection.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DE (Completed) NO (Completed) GB (Completed) AT (Completed) GR (Completed) IT (Completed) NL (Completed) DK (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005034-20 Sponsor Protocol Number: 228-13/06 Start Date*: 2007-03-08
    Sponsor Name:Klinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf
    Full Title: Doppelblinde, prospektiv-randomisierte, intraindividuell-halbseitenvergleichende Studie zur klinischen Wirksamkeit von Verrumal® Lsg. bei aktinischen Keratosen gegen Vehikel: Investigator-initiiert...
    Medical condition: Actinic keratosis is a precancerous skin growth usually caused by sun exposure. Symptoms: Rough and dry textured skin lesion, macule, patch, or growth on the skin Located on sun-exposed areas. Acti...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000614 Actinic keratosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001987-39 Sponsor Protocol Number: CDRB436X2X02B Start Date*: 2017-12-18
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (...
    Medical condition: Patients with BRAF V600 mutation positive
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018545 10027481 Metastatic melanoma LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006196-42 Sponsor Protocol Number: CJDQ443E12101 Start Date*: 2022-08-16
    Sponsor Name:Novartis Pharma AG
    Full Title: KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
    Medical condition: adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    25.1 100000004850 10069759 KRAS mutation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003596-35 Sponsor Protocol Number: MEK116540 Start Date*: 2015-12-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subj...
    Medical condition: Children and Adolescents with Cancers Harboring V600 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000873-26 Sponsor Protocol Number: CLXH254C12201 Start Date*: 2020-11-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV6...
    Medical condition: previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) AT (Completed) NL (Ongoing) PL (Completed) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001830-24 Sponsor Protocol Number: CA209-9N9 Start Date*: 2021-04-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2018-004362-34 Sponsor Protocol Number: CA209-8TT Start Date*: 2020-03-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
    Medical condition: pan tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) NO (Completed) PL (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Completed) PT (Completed) CZ (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006276-16 Sponsor Protocol Number: CTRIAL-IE-20-27 Start Date*: 2022-03-09
    Sponsor Name:Cancer Trials Ireland
    Full Title: PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine.
    Medical condition: Metastatic refractory pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005053-25 Sponsor Protocol Number: TRAM Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Mother and Child
    Full Title: Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001627-39 Sponsor Protocol Number: GOG-0281 Start Date*: 2014-10-24
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer (GOG-0281)
    Medical condition: Recurrent low grade serous ovarian or peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-001691-41 Sponsor Protocol Number: EMN29 Start Date*: 2021-12-28
    Sponsor Name:European Myeloma Network
    Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002851-27 Sponsor Protocol Number: C16-40 Start Date*: 2018-10-08
    Sponsor Name:INSERM
    Full Title: MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS - A phase III study
    Medical condition: Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 17:40:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA